Here are four things to know:
1. The higher end of the price target is estimated at $34 while the lower end of the price target is $12, according to the rating issued from 12 Wall Street analysts.
2. The 52-week high of the share price is $29.97 and the 52-week low is $14.71.
3. The company has a market cap of $2,531 million.
4. The company is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.
More articles on GI/endoscopy:
3 GI physicians making headlines – June 5, 2015
PAION begins 2nd phase 3 clinical trial of short acting anesthetic Remimazolam
5 most read GI/endoscopy stories – June 1 to June 5
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
